IMRIS fourth quarter total revenues increase 37% to $20.1 million

Published on March 5, 2013 at 11:16 PM · No Comments

IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today reported its results for the fourth quarter and full year of 2012.  All figures are reported in US dollars.

Highlights:

  • Fourth quarter order bookings of $24 million contribute to record full year 2012 orders of $89 million
  • Backlog increases 29% in 2012 to $123 million at December 31, 2012
  • Quarterly revenues of $20 million second highest in Company's history
  • Operational leadership team strengthened with new appointments
  • First VISIUS Surgical Theatre in Japan begins clinical operation

During the fourth quarter of 2012, IMRIS received orders for two VISIUS Surgical Theatres bringing total order bookings in 2012 to $89 million including ten new VISIUS Surgical Theatre sales and fourteen service contracts.  Revenues were $20.1 million in the quarter compared with $14.7 million in the fourth quarter of 2011 and for all of 2012 were $52.4 million compared with $51.8 million in the same period in 2011.  Net loss in the fourth quarter was $6.6 million, compared with $5.0 million in the fourth quarter of 2011.  Net loss in 2012 was $27.8 million compared with $20.9 million during the same period in 2011.

Financial Highlights:

Fourth Quarter and Annual Results:

Revenues

Total revenues increased by 37% to $20.1 million in the fourth quarter of 2012 compared with $14.7 million in the fourth quarter of 2011.  VISIUS Surgical Theatre delivery activities increased over the same period in 2011 resulting in a $4.8 million increase in system revenue compared to the same quarter in 2011. Also contributing to the improvement in fourth quarter results were service contract revenues which increased 61% to $1.6 million as a result of an increase in the installed base of VISIUS Surgical Theatres which have transitioned from warranty to service programs.

For the year ended December 31, 2012, total revenues were $52.4 million compared with $51.8 million in 2011.  Contributing to the increase in 2012, were service contract revenues which increased by 55% to $5.1 million reflecting a larger installed base of VISIUS Surgical Theatres in 2012 versus 2011. Revenues for all of 2012 from the installation of VISIUS Surgical Theatres were slightly lower at $47.3 million compared with $48.5 million in 2011, reflecting a product mix with a slightly higher average sale price per project in 2011.

Gross Profit

Gross profit was $7.0 million in the fourth quarter compared with $4.8 million in Q4 2011. The fourth quarter 2012 gross profit as a percentage of sales was 34.8% compared to 32.9% in Q4 2011. The higher year-over-year gross profit performance in the fourth quarter was attributable to increased installations and higher margined system installations. Gross profit for the twelve months ended December 31, 2012 was marginally higher at $17.8 million compared with $17.7 million during the same period in 2011. As expected, full year 2012 gross profit as a percentage of sales at 34.0% was comparable to performance in 2011 which was 34.1%. 

Operating Expenses

Operating expenses continue to focus on investment to grow the business.

Total operating expenses increased by $7.1 million to $45.3 million in 2012. Research and development included higher expenses of $4.4 million primarily for the commercialization of IMRIS's image guided surgical robotics system, intraoperative CT and MR guided radiation therapy product.  Restructuring expenses for the relocation of the Company's operations from Winnipeg to Minneapolis added $1.4 million. Customer support and operations expense increased from a year earlier, primarily to support growth in the business. Amortization increased by $0.5 million to $4.1 million, reflecting net additions in fixed assets.  Total operating expenses in the fourth quarter of 2012 increased by $3.2 million to $13.3 million, with the increase attributable to the same general factors that resulted in higher full year 2012 operating expenses.

Adjusted EBITDA and Operating Loss

Adjusted EBITDA in the fourth quarter of 2012 was negative $4.8 million compared with negative $4.1 million in the fourth quarter of 2011.  For all of 2012 adjusted EBITDA was negative $21.9 million versus $15.7 million in 2011.  Operating loss was $6.3 million in the fourth quarter of 2012 and $27.5 million for the twelve months ended December 31, 2012. This compares with operating losses of $5.3 million and $20.6 million in the fourth quarter and twelve months of 2011 respectively. The year over year changes in fourth quarter adjusted EBITDA and operating losses are due higher operating expenses partially offset by higher gross profit. The increase in negative adjusted EBITDA and operating losses in full year 2012 is due to higher operating expenses primarily related to research and development, relocation and higher customer support and operations expense.

Net Loss

Net loss for the fourth quarter of 2012 was $6.6 million, compared with $5.0 million in the fourth quarter of 2011. The higher net losses in the fourth quarter reflect increased operating expenses, partially offset by higher gross profit arising from increased installation activity in the Q4 2012 period. For all of 2012, net loss was $27.8 million compared with $20.9 million in 2011.  The higher net losses in full year 2012 are attributable to increased operating expenses.

Liquidity and Capital Resources

Cash and restricted cash at December 31, 2012 totaled $21.0 million.  In addition, the Company had accounts receivable of $11.1 million. These funds, together with ongoing operating cash flow, will be used to fund the Company's working capital and general corporate purposes.

Backlog

During the fourth quarter of 2012, $24.4 million in new orders were received and $20.1 million of backlog was converted into revenues.  The change in the US dollar versus the foreign currencies of the orders in backlog resulted in a $0.3 million increase in the value of the backlog. Backlog at December 31, 2012 was $122.5 million and comprised of $69.2 million of system orders and $53.3 million in service contracts. 

Other Developments

Maurice Holloman appointed Executive Vice President Operations - In December 2012, Maurice Holloman joined IMRIS as Executive Vice President Operations. He has extensive leadership background in Project Engineering, Site Operations Management, Plant Management, Supply Chain Management and Operations. Prior to joining IMRIS he was with Medtronic since 2005 in senior operational leadership positions, and Novartis Nutrition Corporation as Director, Supply Chain Operations.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
(optional)
Post